Sunday, June 21

Browsing: CLDN18.2positive

Research

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

By NewsCancerMarch 16, 20260

Competing interests K.S. reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda Pharmaceutical, Ono Pharmaceutical,…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT

How can we help our fathers live longer?

Cancer research lab's £6m extra annual cash boost

Browsing: CLDN18.2positive

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT

How can we help our fathers live longer?

Cancer research lab's £6m extra annual cash boost

Restoring O-glycosylation and expression of MUC2 limits progression of colorectal cancer

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT

How can we help our fathers live longer?

Cancer research lab's £6m extra annual cash boost

Restoring O-glycosylation and expression of MUC2 limits progression of colorectal cancer

Latest Post

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT

How can we help our fathers live longer?

Cancer research lab's £6m extra annual cash boost

Subscribe to Updates

What's Hot

Browsing: CLDN18.2positive